Alteconazole is a triazole that was under development by Knoll Pharmaceuticals as both an orally and topically active antifungal drug. MICs were reported against Microsporum ferruginium, C. albicans, and Mucor pusilis. In mice, alteconazole administered orally produced greater antifungal activity than the reference compounds assayed. In a rat model of experimental vaginal candidiasis, alteconazole was active following both oral and topical administration. Alteconazole developed for the treatment of superficial mycoses, dermatomycoses, and systemic mycoses.